Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

CMV Viremia · Heart Transplant Infection · Heart Transplant Failure and Rejection

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

NYP-Weill Cornell, New York, New York, United States
Contact: Study coordinator (David Majure, MD) · dtm9002@med.cornell.edu · 6469629062
Contact: Study coordinator (Adel T Alnatour, BS)
Contact: Principal Investigator (David Majure, MD)
Columbia University/NYP Milstein Hospital, New York, New York, United States
Contact: Study coordinator (Afsana Rahman, MD) · ar3262@cumc.columbia.edu · 2123054600
Contact: Study coordinator (Adel T Alnatour, BS)
Contact: Principal Investigator (Afsana Rahman, MD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection

Brain Cancer Metastatic · CMV Viremia

Abroad (travel likely)RecruitingPHASE2

Houston, United States

Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients

CMV Viremia

Abroad (travel likely)RecruitingPHASE2

Ljubljana, Slovenia

Expansion of Virus-Specific Lymphocytes for Cell Therapy

CMV Viremia · CMV

Abroad (travel likely)RecruitingPHASE1

São Paulo, Brazil

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Kidney Transplantation, Cytomegalovirus Infections · EBV Infection · Antiviral Prophylaxis

Abroad (travel likely)Recruiting

Taipei, Taiwan